{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:56:27Z","timestamp":1760853387060},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.3816\/clm.2005.n.046","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:34Z","timestamp":1221095434000},"page":"191-199","source":"Crossref","is-referenced-by-count":26,"title":["Marked Clinical Activity of the Proteasome Inhibitor Bortezomib in Patients with Follicular and Mantle-Cell Lymphoma"],"prefix":"10.3816","volume":"6","author":[{"given":"Owen A.","family":"O'Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2005.n.046_bib1","first-page":"213","article-title":"Follicular lymphoma: expanding therapeutic options","volume":"19","author":"Ganti","year":"2005","journal-title":"Oncology"},{"key":"10.3816\/CLM.2005.n.046_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1182\/blood.V83.4.881.881","article-title":"Treatment approaches to the low-grade lymphomas","volume":"83","author":"Horning","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.046_bib3","first-page":"2655","article-title":"Can we cure indolent lymphomas?","volume":"3","author":"Cabanillas","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2005.n.046_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1365-2141.2003.04761.x","article-title":"Molecular basis of mantle cell lymphoma","volume":"124","author":"Bertoni","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.046_bib5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study","volume":"85","author":"Fisher","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.046_bib6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2005.n.046_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1146\/annurev.bi.61.070192.003553","article-title":"The ubiquitin system for protein degradation","volume":"61","author":"Hershko","year":"1992","journal-title":"Annu Rev Biochem"},{"key":"10.3816\/CLM.2005.n.046_bib8","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1016\/S0021-9258(18)53218-X","article-title":"The multicatalytic and 26 S proteases","volume":"268","author":"Rechsteiner","year":"1993","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2005.n.046_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1359-6446(03)02647-3","article-title":"Potential for proteasome inhibition in the treatment of cancer","volume":"8","author":"Adams","year":"2003","journal-title":"Drug Discov Today"},{"key":"10.3816\/CLM.2005.n.046_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006321828515","article-title":"Proteasome inhibition: a new strategy in cancer treatment","volume":"18","author":"Adams","year":"2000","journal-title":"Invest New Drugs"},{"key":"10.3816\/CLM.2005.n.046_bib11","doi-asserted-by":"crossref","first-page":"12504","DOI":"10.1073\/pnas.95.21.12504","article-title":"Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1","volume":"95","author":"Nussbaum","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2005.n.046_bib12","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1074\/jbc.274.6.3363","article-title":"The sizes of peptides generated from protein by mammalian 26 and 20 S proteasomes. Implications for understanding the degradative mechanism and antigen presentation","volume":"274","author":"Kisselev","year":"1999","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2005.n.046_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1083\/jcb.150.1.119","article-title":"The regulatory complex of Drosophila melanogaster 26S proteasomes. Subunit composition and localization of a deubiquitylating enzyme","volume":"150","author":"Holzl","year":"2000","journal-title":"J Cell Biol"},{"key":"10.3816\/CLM.2005.n.046_bib14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S proteasome: a molecular machine designed for controlled proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"10.3816\/CLM.2005.n.046_bib15","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1093\/emboj\/17.24.7151","article-title":"The ubiquitin-proteasome pathway: on protein death and cell life","volume":"17","author":"Ciechanover","year":"1998","journal-title":"Embo J"},{"key":"10.3816\/CLM.2005.n.046_bib16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1471-4914(02)02375-4","article-title":"NF-kappaB as a therapeutic target in cancer","volume":"8","author":"Orlowski","year":"2002","journal-title":"Trends Mol Med"},{"key":"10.3816\/CLM.2005.n.046_bib17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.046_bib18","article-title":"A multicenter experience with single agent bortezomib in non-Hodgkin's lymphoma reveals marked difference in sub-type sensitivity to proteasome inhibition","volume":"104","author":"O'Connor","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.046_bib19","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of bortezomib in relapsed\/refractory B-Cell NHL","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.046_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.608.608","article-title":"Phase II trial of bortezomib in mantle cell lymphoma","volume":"104","author":"Belch","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.046_bib21","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V104.11.3294.3294","article-title":"Mantle cell and follicular lymphoma samples demonstrate differing sensitivity to bortezomib in a primary culture system","volume":"104","author":"Maharaj","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.046_bib22","doi-asserted-by":"crossref","first-page":"389a","DOI":"10.1182\/blood.V104.11.1386.1386","article-title":"Phase II clinical study of bortezomib (VELCADE) in patients with relapsed\/refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's disease (HD)","volume":"104","author":"Strauss","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.046_bib23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.046_bib24","doi-asserted-by":"crossref","first-page":"15671","DOI":"10.1073\/pnas.95.26.15671","article-title":"Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis","volume":"95","author":"Palombella","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2005.n.046_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.cb.10.110194.002201","article-title":"Structure, regulation and function of NF-kappa B","volume":"10","author":"Siebenlist","year":"1994","journal-title":"Annu Rev Cell Biol"},{"key":"10.3816\/CLM.2005.n.046_bib26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.immunol.14.1.649","article-title":"The NF-kappa B and I kappa B proteins: new discoveries and insights","volume":"14","author":"Baldwin","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.3816\/CLM.2005.n.046_bib27","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V97.9.2798","article-title":"Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin\/Reed-Sternberg cells","volume":"97","author":"Hinz","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.046_bib28","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1038\/sj.onc.1205483","article-title":"NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells","volume":"21","author":"Heckman","year":"2002","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2005.n.046_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0092-8674(86)90362-4","article-title":"Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2\/immunoglobulin transcript resulting from the t(14;18) translocation","volume":"47","author":"Cleary","year":"1986","journal-title":"Cell"},{"key":"10.3816\/CLM.2005.n.046_bib30","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1126\/science.3929382","article-title":"The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining","volume":"229","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"key":"10.3816\/CLM.2005.n.046_bib31","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1073\/pnas.83.14.5214","article-title":"Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma","volume":"83","author":"Tsujimoto","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CLM.2005.n.046_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NFkappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J Immunol"},{"key":"10.3816\/CLM.2005.n.046_bib33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0092-8674(93)90499-G","article-title":"The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases","volume":"75","author":"Harper","year":"1993","journal-title":"Cell"},{"key":"10.3816\/CLM.2005.n.046_bib34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1083\/jcb.127.2.467","article-title":"Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase)","volume":"127","author":"Tassan","year":"1994","journal-title":"J Cell Biol"},{"key":"10.3816\/CLM.2005.n.046_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/349132a0","article-title":"Cyclin is degraded by the ubiquitin pathway","volume":"349","author":"Glotzer","year":"1991","journal-title":"Nature"},{"key":"10.3816\/CLM.2005.n.046_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0092-8674(94)90572-X","article-title":"Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals","volume":"78","author":"Polyak","year":"1994","journal-title":"Cell"},{"key":"10.3816\/CLM.2005.n.046_bib37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(94)90573-8","article-title":"p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21","volume":"78","author":"Toyoshima","year":"1994","journal-title":"Cell"},{"key":"10.3816\/CLM.2005.n.046_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/(SICI)1097-0320(19970701)28:3<243::AID-CYTO9>3.0.CO;2-E","article-title":"Detailed analysis of cell cycle kinetics upon proteasome inhibition","volume":"28","author":"Machiels","year":"1997","journal-title":"Cytometry"},{"key":"10.3816\/CLM.2005.n.046_bib39","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7624798","article-title":"Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27","volume":"269","author":"Pagano","year":"1995","journal-title":"Science"},{"key":"10.3816\/CLM.2005.n.046_bib40","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1182\/blood.V100.8.2950","article-title":"Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index","volume":"100","author":"Lim","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.046_bib41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V95.2.619","article-title":"Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma","volume":"95","author":"Chiarle","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.046_bib42","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1365-2141.2003.04438.x","article-title":"Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells","volume":"122","author":"Bogner","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.046_bib43","first-page":"1145","article-title":"Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines","volume":"9","author":"Ling","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2005.n.046_bib44","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1002\/cncr.10876","article-title":"Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma","volume":"95","author":"Vaskivuo","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CLM.2005.n.046_bib45","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.4049\/jimmunol.166.5.3130","article-title":"Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells","volume":"166","author":"Marshansky","year":"2001","journal-title":"J Immunol"},{"key":"10.3816\/CLM.2005.n.046_bib46","first-page":"841","article-title":"PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis","volume":"1","author":"Ling","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"16 suppl","key":"10.3816\/CLM.2005.n.046_bib47","first-page":"575s","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL); preliminary results of the PINNACLE study","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.046_bib48","article-title":"Active combination therapy of bortezomib and rituximab in vitro and in vivo DLBCL model","author":"deVos","year":"2004","journal-title":"Proc American Association for Cancer Research"},{"key":"10.3816\/CLM.2005.n.046_bib49","article-title":"Phase 2 study of bortezomib and rituximab in patients with indolent non-Hodgkin's lymphoma (NHL)","volume":"16","author":"Saleh","year":"2005","journal-title":"Ann Oncol"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T07:49:50Z","timestamp":1631778590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S1557919011703924"],"URL":"https:\/\/doi.org\/10.3816\/clm.2005.n.046","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}